Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

InMed Pharmaceuticals Inc INM

InMed Pharmaceuticals Inc. is a clinical-stage pharmaceutical company. The Company is engaged in developing a pipeline of prescription-based products, including rare cannabinoids and cannabinoid analogs, targeting the treatment of diseases with high unmet medical needs, as well as developing proprietary manufacturing technologies to produce rare cannabinoids for sale in the health and wellness industry. Its segments include InMed Pharmaceuticals and BayMedica. The InMed Pharmaceuticals segment is engaged in research and development of cannabinoid-based pharmaceutical products. The BayMedica segment is focused on developing manufacturing technologies to produce rare cannabinoids for sale in the health and wellness industry. Its two product candidates include INM-755 and INM-088. INM-755 is developed as a topical skin cream formulation containing cannabinol (CBN) for the treatment of symptoms related to Epidermolysis Bullosa (EB). INM-088 is used for the treatment of glaucoma.


NDAQ:INM - Post by User

Bullboard Posts
Comment by montreal10on Jun 28, 2004 1:42pm
162 Views
Post# 7657358

RE: MCS featured in Stockhouse Editorial today

RE: MCS featured in Stockhouse Editorial todayMeridex Software ($1.16) Meridex (TSXV: V.MSC) develops management software for small and medium sized business and in Q1 financials, reported that they now work with 500 to 800 clients on a regular monthly basis. It is our understanding that the company's client base continues to grow and if/when the right companies come along, they are more than prepared to also grow through acquisition. There is no point wasting space to discuss what they do in detail, so please visit the Meridex website and also that of their subsidiary at www.tillica.com. The CEO is Dr. Intesar Ramley who in May bought a $600,000 private placement in this company at $1.60 with $1.75 warrants. Obviously this is a very solid vote of confidence in Meridex. We believe MSC will receive analyst coverage out of Europe in the coming months (they recently obtained a listing on the Frankfurt Stock Exchange) and this increased exposure should help the share price considerably. It's impossible to tell how long selling will continue at this level, but for anyone interested in the tech sector, this is a good time to research Meridex much closer.
Bullboard Posts